BeeKeeperAI Enables Icahn School of Medicine at Mount Sinai and Morehouse School of Medicine to Test the Performance of Healthcare AI Models in Their Environments
AUSTIN, Texas--(BUSINESS WIRE)--BeeKeeperAI®, Inc., a pioneer in privacy-enhancing, multi-party collaboration software for AI development and deployment, today announced that Morehouse School of Medicine (MSM) and the Icahn School of Medicine at Mount Sinai will utilize BeeKeeperAI's EscrowAI® platform to rapidly test AI models on their real-world, multi-modal data in chronic heart failure (CHF). This milestone represents the first operational deployment certified under the Coalition for Health AI (CHAI)'s assurance service provider certification process, setting a precedent for how AI models can be responsibly tested and brought to market faster across institutions and populations.
'As we advance our mission to enable responsible, evidence-based AI, this is just the first of many collaborations where CHAI-certified service providers and health institutions will work together to ensure AI serves all patients,' said Dr. Brian Anderson, CEO of CHAI. 'We're proud to see Morehouse School of Medicine, Icahn School of Medicine, and BeeKeeperAI leading the way in developing trusted AI solutions.'
MSM, Icahn School of Medicine, and BeeKeeperAI are all members of CHAI and have adopted its scorecard model for algorithm developers seeking to demonstrate real-world performance to the broader market. Their shared goal is to accelerate the responsible development, validation, and market adoption of AI that improves clinical decision-making, reduces hospital readmissions, and ensures needs-based outcomes—particularly for patients with lower resource availability who face disproportionate risk from chronic heart failure.
'To bring healthcare AI to market, speed matters—but so does trust,' said Dr. Michael Blum, MD, Co-founder and CEO of BeeKeeperAI. 'With EscrowAI, Icahn School of Medicine and Morehouse School of Medicine can enable AI developers to securely test their models on high-value, real-world data in days—not months—while preserving patient privacy and model IP. This is how we unlock faster, scalable, and equitable innovation in healthcare.'
The curated datasets, based on shared specifications, include clinical, demographic, and social determinants of health data—offering a rare opportunity to assess algorithm performance across institutions serving predominantly resource-limited populations.
'Morehouse School of Medicine is committed to ensuring all patients have the opportunity to achieve optimal outcomes from treatment for chronic heart failure,' said Muhammed Y. Idris, PhD, Assistant Professor, Medicine and Co-Director, Center for the Validation of Digital Health Technologies and Clinical Algorithms at Morehouse School of Medicine. 'By enabling AI developers to securely compute on our data, we're creating the foundation for algorithms that can reduce readmissions and mortality for those most at risk.'
'AI has the potential to transform clinical care delivery, but only if models are proven to be accurate, safe, and effective in real-world and diverse settings,' said Tanvir Kahlon, MD, MBA, Assistant Professor, Advanced Heart Failure and Transplant, Interventional Cardiology at Icahn School of Medicine at Mount Sinai. 'Our work with BeeKeeperAI and Morehouse makes that assurance possible—without compromising privacy or integrity.'
Accelerating Trustworthy & Responsible AI with Privacy-Enhancing Technology
BeeKeeperAI's EscrowAI platform allows AI model testing inside a data steward's secure environment using Trusted Execution Environments (TEEs) with confidential computing—ensuring data privacy, regulatory compliance, and protection of IP throughout the process. As a recently certified CHAI Assurance Service Provider, BeeKeeperAI meets the highest standards for ethical and secure AI validation.
EscrowAI replaces lengthy data access and contracting delays with push-button, compliant testing workflows —compressing timelines and accelerating time-to-value for algorithm developers. Developers can test and prove model performance on real-world, regulated data in a SOC 2-compliant environment aligned with CHAI's data integrity and scorecard framework. The resulting performance reports are immutable, transparent, and reproducible—creating a fast, scalable path to market evaluation and adoption.
CHAI Assurance: A Market-Based Model for Responsible AI
This collaboration reflects a broader shift in healthcare AI—from evaluations too often based on marketing presentations to more evidence-based, transparent assurance. CHAI's conflict-of-interest and ethics policies ensure independent oversight, while BeeKeeperAI's infrastructure delivers privacy-protected reproducibility, regulatory-grade audit trails, and speed-to-deployment. Together, they support faster validation and value-based procurement for AI solutions that work, including in populations that need them most.
As part of this initiative, Icahn School of Medicine and Morehouse School of Medicine will be publishing data catalogs, enabling independent AI testing and validation to support the new benchmark for healthcare AI transparency and efficiency.
About BeeKeeperAI
BeeKeeperAI is the pioneer in privacy-enhancing technologies, integrating Trusted Execution Environments with confidential computing to accelerate AI validation and deployment in regulated sectors, including healthcare and government. BeeKeeperAI enables real-world data to be used safely and securely, without ever exposing it—empowering institutions to bring trusted AI to market faster. Learn more at beekeeperai.com.
Icahn School of Medicine at Mount Sinai is an investor in BeeKeeperAI.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 minutes ago
- Business Upturn
DRiV Introduces Walker® OE-Quality Starters, Alternators and Air Conditioning Parts – All Backed by 3-Year Warranty
KONTICH, Belgium, June 06, 2025 (GLOBE NEWSWIRE) — DRiV, the aftermarket business unit of Tenneco, is once again expanding the reach of its popular Walker® brand with the introduction of two comprehensive new product ranges: Walker remanufactured starters & alternators and Walker air conditioning parts. Each new range, available in June, joins all Walker products – from emissions control to turbochargers and more – in delivering guaranteed OE quality, exceptional coverage, and the Walker brand's popular 3-year warranty*. 'Walker is setting the standard for delivering new opportunities for profitable growth of installer businesses,' said Julien Russeau, Product Management Director, DRiV. 'And every Walker part offers the impressive value of 'The Walker Way,' with product quality standards and technical support that empower installers to do the job right, every time.' Walker starters and alternators are fully renewed products backed by Walker engineers who set the standard in product quality. Each fully renewed unit begins with a high-quality OE core and is produced strictly within an OE-certified facility located in Europe. These units are also tested in accordance with OE specifications to help ensure they perform like brand-new units. Walker air conditioning parts empower installers to provide a true OE-quality repair for virtually any light vehicle – including many EV models – operated in Europe. These parts include Walker fully renewed compressors and brand-new condensers, dryers, evaporators, expansion valves, and internal blowers. Each part is engineered by Walker experts to meet OE quality specifications and deliver seamless compatibility, easy installation, and outstanding performance. About DRiV DRiV, a business group of Tenneco, is a leader in the automotive aftermarket, committed to enhancing vehicle performance through innovative solutions and exceptional engineering. With a diverse portfolio of 31 renowned brands, the focus is on delivering high-quality auto parts that ensure optimal functionality and reliability. This commitment extends across automotive and industrial sectors, featuring key brands such as MONROE®, MOOG®, Champion®, Wagner®, and Ferodo®, all dedicated to keeping the world moving efficiently. About Tenneco Tenneco is one of the world's leading designers, manufacturers, and marketers of automotive products for original equipment and aftermarket customers. Through our DRiV, Performance Solutions, Clean Air, Powertrain and Ignition business groups, Tenneco is driving advancements in global mobility by delivering technology solutions for light vehicle, commercial truck, off-highway, industrial, motorsport, and the aftermarket. Visit to learn more . CONTACT: Simonetta EspositoSenior Manager Global CommunicationsTenneco [email protected]
Yahoo
28 minutes ago
- Yahoo
Burning Rock Reports First Quarter 2025 Financial Results
GUANGZHOU, China, June 06, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the 'Company' or 'Burning Rock'), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2025. Recent Business Updates Therapy Selection and MRD Personalized Minimal Residual Disease (MRD) product, CanCatch® Custom supports advancement in oesophageal squamous cell carcinoma（OSCC）treatment, with results published in the Molecular Cancer in May 2025. The study is a two-arm, multicenter, randomized, double-blind phase 2 study, comparing the efficacy of systemic treatment combining nCT with immunotherapy against nCT alone for OSCC patients. The study demonstrates that Perioperative Nivolumab plus chemotherapy is a viable and safe option for systemically treating locally advanced resectable OSCC, and monitoring minimal residual disease through ctDNA could be potentially valuable for assessing the effectiveness of adjuvant therapy and for prognostic evaluation in a systemic manner. Presented study results on non-small cell lung cancer and gastrointestinal stromal tumor (GIST) at the ASCO in June 2025. 'Personalized tumor-informed ctDNA has the potential to inform recurrence in high-risk locally advanced stage GIST patients, especially for patients with irregular adjuvant therapy' and 'MUSETALK-Lung01 (MUltiomics SEquencing Technique AppLication Kick-start) is a prospective, longitudinal, observational study designed to evaluate the clinical utility of a tumor-naïve ctDNA assay in patients with early-stage non-small cell lung cancer (NSCLC).' Presented multiple study results at the 2025 AACR in April, showcasing the clinical utility of the tumor-informed personalized MRD assay (CanCatch® Custom) and the tumor-naïve methylation-based MRD assay. First Quarter 2025 Financial Results Revenues were RMB133.1 million (US$18.3 million) for the three months ended March 31, 2025, representing a 5.9% increase from RMB125.6 million for the same period in 2024. Revenue generated from central laboratory business was RMB38.3 million (US$5.3 million) for the three months ended March 31, 2025, representing a 19.6% decrease from RMB47.6 million for the same period in 2024, primarily attributable to a decrease in the number of tests, as we continued to focus on our in-hospital business. Revenue generated from in-hospital business was RMB57.7 million (US$7.9 million) for the three months ended March 31, 2025, representing a 0.5% increase from RMB57.4 million for the same period in 2024, driven by a continuous growth in sales volume. Revenue generated from pharma research and development services was RMB37.1 million (US$5.1 million) for the three months ended March 31, 2025, representing a 79.9% increase from RMB20.6 million for the same period in 2024, primarily attributable to increased development and testing services performed for our pharma customers, and several milestones of our pharma programs were achieved. Cost of revenues was RMB35.7 million (US$4.9 million) for the three months ended March 31, 2025, representing a 10.6% decrease from RMB39.9 million for the same period in 2024, primarily due to a decrease in cost of central laboratory business, which was in line with the decrease in revenue generated from this business. Gross profit was RMB97.4 million (US$13.4 million) for the three months ended March 31, 2025, representing a 13.7% increase from RMB85.7 million for the same period in 2024. Gross margin was 73.2% for the three months ended March 31, 2025, compared to 68.2% for the same period in 2024. By channel, gross margin of central laboratory business was 84.1% for the three months ended March 31, 2025, compared to 77.7% during the same period in 2024, primarily due to a reduction in material and labor costs resulted from cost optimization and control measures and a decreased depreciation and rental cost in relation to our laboratory of Guangzhou headquarter; gross margin of in-hospital business was 76.1% for the three months ended March 31, 2025, compared to 68.3% during the same period in 2024, primarily due to the same reason; gross margin of pharma research and development services was 57.5% for the three months ended March 31, 2025, compared to 46.1% during the same period of 2024, primarily due to the cost optimization measures and an increase in test volume of higher margin projects. Non-GAAP gross profit, which excludes depreciation and amortization expenses, RMB100.7 million (US$13.9 million) for the three months ended March 31, 2025, representing an 8.3% increase from RMB93.0 million for the same period in 2024. Non-GAAP gross margin was 75.6% for the three months ended March 31, 2025, compared to 74.0% for the same period in 2024. Operating expenses were RMB112.6 million (US$15.5 million) for the three months ended March 31, 2025, representing a 46.8% decrease from RMB211.5 million for the same period in 2024. The decrease was primarily driven by budget control measures and headcount reduction to improve the Company's operating efficiency. Research and development expenses were RMB40.4 million (US$5.6 million) for the three months ended March 31, 2025, representing a 38.8% decrease from RMB66.0 million for the same period in 2024, primarily due to (i) a decrease in amortized expense on share-based compensation; (ii) a decrease in the expenditure for detection research and (iii) a decrease in depreciation and amortization. Selling and marketing expenses were RMB40.9 million (US$5.6 million) for the three months ended March 31, 2025, representing a 12.7% decrease from RMB46.9 million for the same period in 2024, primarily due to (i) a decrease in staff cost resulted from the reorganization of our sales department to improve operating efficiency and (ii) a decrease in depreciation and amortization. General and administrative expenses were RMB31.3 million (US$4.3 million) for the three months ended March 31, 2025, representing a 68.3% decrease from RMB98.7 million for the same period in 2024, primarily due to (i) a decrease in amortized expense on share-based compensation; (ii) a decrease in depreciation and amortization; (iii) a decrease in staff cost resulted from the reorganization; and (iv) a decrease in operating lease expense for office building. Net loss was RMB13.5 million (US$1.9 million) for the three months ended March 31, 2025, compared to RMB121.5 million for the same period in 2024. Cash, cash equivalents and restricted cash were RMB497.4 million (US$68.5 million) as of March 31, 2025. Exchange Rate Information This press release contains translations of certain Renminbi amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars and from U.S. dollars to Renminbi are made at a rate of RMB7.2567 to US$1.00, the exchange rate on March 31, 2025, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the Renminbi or U.S. dollars amounts referred could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all. About Burning Rock Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. For more information about Burning Rock, please visit: Safe Harbor Statement This press release contains forward-looking statements. These statements constitute 'forward-looking' statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'target,' 'confident' and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock's beliefs and expectations, are forward-looking statements. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock's control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law. Non-GAAP Measures In evaluating the business, the Company considers and uses non-GAAP measures, such as non-GAAP gross profit and non-GAAP gross margin, as supplemental measures to review and assess operating performance. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America ('U.S. GAAP'). The company defines non-GAAP gross profit as gross profit excluding depreciation and amortization. The company defines non-GAAP gross margin as gross margin excluding depreciation and amortization. The company presents these non-GAAP financial measures because they are used by management to evaluate operating performance and formulate business plans. The company believe non-GAAP gross profit and non-GAAP gross margin excluding non-cash impact of depreciation and amortization reflect the company's ongoing business operations in a manner that allows more meaningful period-to-period comparisons. Contact: IR@ Selected Operating Data As of March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 March 31, 2025 In-hospital Channel: Pipeline partner hospitals(1) 28 29 30 29 30 Contracted partner hospitals(2) 59 59 61 63 63 Total number of partner hospitals 87 88 91 92 93(1) Refers to hospitals that are in the process of establishing in-hospital laboratories, laboratory equipment procurement or installation, staff training or pilot testing using the Company's products. (2) Refers to hospitals that have entered into contracts to purchase the Company's products for use on a recurring basis in their respective in-hospital laboratories the Company helped them establish. Kit revenue is generated from contracted hospitals. Selected Financial Data For the three months ended Revenues March 31, 2024 June 30, 2024 September 30, 2024 December 31, 2024 March 31, 2025 (RMB in thousands) Central laboratory channel 47,614 48,773 39,984 39,278 38,296 In-hospital channel 57,387 59,872 63,769 43,464 57,687 Pharma research and development channel 20,622 26,888 24,891 43,280 37,099 Total revenues 125,623 135,533 128,644 126,022 133,082 For the three months ended Gross profit March 31,2024 June 30,2024 September 30,2024 December 31,2024 March 31,2025 (RMB in thousands) Central laboratory channel 37,002 38,424 33,262 33,153 32,191 In-hospital channel 39,192 44,058 46,580 29,563 43,895 Pharma research and development channel 9,500 12,956 12,004 26,706 21,315 Total gross profit 85,694 95,438 91,846 89,422 97,401 For the three months ended Share-based compensation expenses March 31,2024 June 30,2024 September 30,2024 December 31,2024 March 31,2025 (RMB in thousands) Cost of revenues 596 464 289 520 308 Research and development expenses 12,287 12,008 3,180 3,202 1,800 Selling and marketing expenses 508 1,232 1,917 1,353 1,025 General and administrative expenses 55,990 54,407 4,732 2,937 1,413 Total share-based compensation expenses 69,381 68,111 10,118 8,012 4,546 Burning Rock Biotech Limited Unaudited Condensed Statements of Comprehensive Loss (in thousands, except for number of shares and per share data) For the three months ended March 31,2024 June 30,2024 September 30, 2024 December 31,2024 March 31, 2025 March 31, 2025 RMB RMB RMB RMB RMB US$ Revenues 125,623 135,533 128,644 126,022 133,082 18,340 Cost of revenues (39,929 ) (40,095 ) (36,798 ) (36,600 ) (35,681 ) (4,918 ) Gross profit 85,694 95,438 91,846 89,422 97,401 13,422 Operating expenses: Research and development expenses (65,985 ) (64,952 ) (49,150 ) (52,203 ) (40,389 ) (5,566 ) Selling and marketing expenses (46,856 ) (48,907 ) (48,411 ) (46,730 ) (40,888 ) (5,635 ) General and administrative expenses (98,681 ) (92,794 ) (32,874 ) (37,289 ) (31,303 ) (4,314 ) Impairment loss on long-lived assets (35,127 ) Total operating expenses (211,522 ) (206,653 ) (130,435 ) (171,349 ) (112,580 ) (15,515 ) Loss from operations (125,828 ) (111,215 ) (38,589 ) (81,927 ) (15,179 ) (2,093 ) Interest income 4,038 3,187 3,173 1,814 2,581 356 Other income (expense), net 434 (82 ) 1 4,353 (652 ) (90 ) Foreign exchange (loss) gain, net (13 ) 262 (129 ) (220 ) (26 ) (4 ) Loss before income tax (121,369 ) (107,848 ) (35,544 ) (75,980 ) (13,276 ) (1,831 ) Income tax expenses (180 ) (190 ) (201 ) (5,314 ) (224 ) (31 ) Net loss (121,549 ) (108,038 ) (35,745 ) (81,294 ) (13,500 ) (1,862 ) Net loss attributable to Burning Rock Biotech Limited's shareholders (121,549 ) (108,038 ) (35,745 ) (81,294 ) (13,500 ) (1,862 ) Net loss attributable to ordinary shareholders (121,549 ) (108,038 ) (35,745 ) (81,294 ) (13,500 ) (1,862 ) Loss per share for class A and class B ordinary shares: Class A ordinary shares - basic and diluted (1.19 ) (1.05 ) (0.35 ) (0.79 ) (0.13 ) (0.02 ) Class B ordinary shares - basic and diluted (1.19 ) (1.05 ) (0.35 ) (0.79 ) (0.13 ) (0.02 ) Weighted average shares outstanding used in loss per share computation: Class A ordinary shares - basic and diluted 85,219,188 85,271,858 85,902,670 86,036,286 90,291,658 90,291,658 Class B ordinary shares - basic and diluted 17,324,848 17,324,848 17,324,848 17,324,848 17,324,848 17,324,848 Other comprehensive income (loss), net of tax of nil: Foreign currency translation adjustments 590 940 (4,054 ) 6,009 (72 ) (10 ) Total comprehensive loss (120,959 ) (107,098 ) (39,799 ) (75,285 ) (13,572 ) (1,872 ) Total comprehensive loss attributable to Burning Rock Biotech Limited's shareholders (120,959 ) (107,098 ) (39,799 ) (75,285 ) (13,572 ) (1,872 ) Burning Rock Biotech LimitedUnaudited Condensed Consolidated Balance Sheets(In thousands) As of December 31, 2024 March 31,2025 March 31,2025 RMB RMB US$ ASSETS Current assets: Cash and cash equivalents 519,849 495,145 68,233 Restricted cash 2,313 2,261 312 Accounts receivable, net 152,013 159,463 21,974 Contract assets, net 13,855 17,178 2,367 Inventories, net 62,625 65,424 9,016 Prepayments and other current assets, net 25,963 22,072 3,042 Total current assets 776,618 761,543 104,944 Non-current assets: Property and equipment, net 47,152 41,162 5,672 Operating right-of-use assets 53,188 43,804 6,036 Intangible assets, net 421 386 53 Other non-current assets 7,926 7,822 1,078 Total non-current assets 108,687 93,174 12,839 TOTAL ASSETS 885,305 854,717 117,783 Burning Rock Biotech LimitedUnaudited Condensed Consolidated Balance Sheets (Continued)(in thousands) As of December 31,2024 March 31,2025 March 31,2025 RMB RMB US$ LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable 33,747 35,938 4,952 Deferred revenue 117,895 117,200 16,151 Accrued liabilities and other current liabilities 89,498 76,198 10,501 Customer deposits 592 592 82 Current portion of operating lease liabilities 24,567 22,524 3,104 Total current liabilities 266,299 252,452 34,790 Non-current liabilities: Non-current portion of operating lease liabilities 27,754 19,814 2,730 Other non-current liabilities 10,425 10,649 1,467 Total non-current liabilities 38,179 30,463 4,197 TOTAL LIABILITIES 304,478 282,915 38,987 Shareholders' equity: Class A ordinary shares 124 124 17 Class B ordinary shares 21 21 3 Additional paid-in capital 5,002,255 5,005,991 689,844 Treasury stock (63,264 ) (62,453 ) (8,606 ) Accumulated deficits (4,200,261 ) (4,213,761 ) (580,672 ) Accumulated other comprehensive loss (158,048 ) (158,120 ) (21,790 ) Total shareholders' equity 580,827 571,802 78,796 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY 885,305 854,717 117,783 Burning Rock Biotech LimitedUnaudited Condensed Statements of Cash Flows(in thousands) For the three months ended March 31,2024 March 31,2025 March 31,2025 RMB RMB US$ Net cash generated from (used in) operating activities 19,062 (23,527 ) (3,242 ) Net cash used in investing activities (812 ) (1,531 ) (211 ) Net cash used in financing activities (74 ) - - Effect of exchange rate on cash, cash equivalents and restricted cash 5,739 302 43 Net increase in (decrease) cash, cash equivalents and restricted cash 23,915 (24,756 ) (3,410 ) Cash, cash equivalents and restricted cash at the beginning of period 498,247 522,162 71,955 Cash, cash equivalents and restricted cash at the end of period 522,162 497,406 68,545 Burning Rock Biotech LimitedReconciliations of GAAP and Non-GAAP Results For the three months ended March 31,2024 June 30,2024 September 30,2024 December 31,2024 March 31,2025 (RMB in thousands) Gross profit: Central laboratory channel 37,002 38,424 33,262 33,153 32,191 In-hospital channel 39,192 44,058 46,580 29,563 43,895 Pharma research and development channel 9,500 12,956 12,004 26,706 21,315 Total gross profit 85,694 95,438 91,846 89,422 97,401 Add: depreciation and amortization: Central laboratory channel 1,919 1,226 1,277 1,010 562 In-hospital channel 1,524 824 798 623 290 Pharma research and development channel 3,856 4,417 3,846 2,534 2,412 Total depreciation and amortization included in cost of revenues 7,299 6,467 5,921 4,167 3,264 Non-GAAP gross profit： Central laboratory channel 38,921 39,650 34,539 34,163 32,753 In-hospital channel 40,716 44,882 47,378 30,186 44,185 Pharma research and development channel 13,356 17,373 15,850 29,240 23,727 Total non-GAAP gross profit 92,993 101,905 97,767 93,589 100,665 Non-GAAP gross margin： Central laboratory channel 81.7% 81.3% 86.4% 87.0% 85.5% In-hospital channel 70.9% 75.0% 74.3% 69.5% 76.6% Pharma research and development channel 64.8% 64.6% 63.7% 67.6% 64.0% Total non-GAAP gross margin 74.0% 75.2% 76.0% 74.3% 75.6%Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Camfil APC Publishes Comprehensive Guide on Pharmaceutical Dust Collection Strategies for Oral Solid Dose Manufacturing
New Technical Resource Addresses Critical Safety, Compliance, and Operational Efficiency Challenges in OSD Pharmaceutical Production Dust Collection Strategies for Oral Solid Dose Manufacturing Jonesboro, AR, June 05, 2025 (GLOBE NEWSWIRE) -- Camfil APC, a leading manufacturer of industrial dust collectors, today announced the publication of a comprehensive technical guide addressing dust collection strategies for oral solid dose (OSD) pharmaceutical manufacturing. The resource, Pharmaceutical Dust Collection: Strategies for Oral Solid Dose Pharmaceutical Manufacturing, provides industry professionals with essential insights into managing potent compound containment, regulatory compliance, and operational efficiency through advanced air filtration technologies. Addressing Critical Industry Challenges The pharmaceutical manufacturing industry faces complex challenges in maintaining worker safety while ensuring product quality and regulatory compliance. This new guide specifically addresses the unique air quality management requirements of OSD production, where exposure to potent, toxic, and allergenic dusts presents significant risks to both personnel and product integrity. "OSD pharmaceutical manufacturers require specialized dust collection solutions that go beyond standard industrial applications," said Tony Galvin, Pharmaceutical Segment Manager, at Camfil APC. "Our new guide provides the technical depth and practical guidance that process engineers, facility managers, and safety professionals need to implement effective containment strategies." Comprehensive Technical Coverage The guide covers essential aspects of pharmaceutical OSD dust collection implementation, including: Regulatory Framework Navigation: OSHA, NFPA and EPA Designing a Dust Collection System for OSD Production Dust Capture and Conveyance Dust Collector Design and Orientation Primary Filtration Media Dust Containment Explosion Protection Measures for Dust Collection Systems Advanced Filtration Solutions for Pharmaceutical Applications The guide features information on Camfil APC's pharmaceutical OSD dust collection solutions, including: Gold Series Camtain® Dust Collector: Engineered for high-containment applications Quad Pulse Package Compact Dust Collector: Space-efficient solutions for facilities with limited mechanical room availability Each solution incorporates advanced HEPA filtration technology and specialized containment features designed to meet the stringent requirements of OSD pharmaceutical production environments. Industry Expert Insights The guide draws upon extensive experience in pharmaceutical manufacturing applications, providing real-world case studies and implementation examples. Content addresses the specific concerns of cross-functional teams typically involved in dust collection system selection, including process engineers, facilities managers, health and safety professionals, quality assurance teams, and maintenance personnel. "Effective dust collection in pharmaceutical OSD manufacturing requires understanding both the technical requirements and the operational realities of production environments," noted Tony Galvin, Pharmaceutical Segment Manager, at Camfil APC. "This guide bridges that gap by providing practical implementation strategies backed by proven engineering principles." Supporting Pharmaceutical Industry Innovation The guide reflects Camfil APC's ongoing commitment to supporting OSD pharmaceutical manufacturing excellence through advanced dust collection and air filtration technology. As the industry continues to evolve with new compounds, production methods, and regulatory requirements, effective dust collection strategies remain essential for maintaining competitive operations while ensuring worker safety and product quality. Technical Resource Availability The complete pharmaceutical OSD dust collection strategies guide is available immediately through Camfil APC's website at About Camfil APC Camfil APC is a leading manufacturer of dust, mist, and fume collection equipment for industrial applications. With decades of experience in air filtration technology, the company provides engineered solutions for challenging industrial environments, including pharmaceutical manufacturing, food processing, metalworking, and chemical production. Camfil APC's comprehensive product portfolio includes dust collectors, replacement filters, and complete system integration services. The company maintains manufacturing facilities in Jonesboro, Arkansas, and provides technical support, installation, and maintenance services across North America. Camfil APC is part of the global Camfil Group, recognized worldwide for innovation in air filtration technology and commitment to clean air solutions. For more information about Camfil APC's OSD pharmaceutical dust collection solutions, visit Media Contact: Lisa Goetz Schubert b2b 1-610-269-2100 x244 lgoetz@ Technical Contact: Tony Galvin Pharmaceutical Segment Manager Camfil APC 1-612-865-9377 Attachment Dust Collection Strategies for Oral Solid Dose Manufacturing
